Stocksigma LogoStocksigma Logo

Laurus Labs Acquires 60% Stake in Canada-Based Galenvs Sciences for USD 3.75 Million

Laurus Labs' board approved acquiring a 60% stake in Canada-based CRO/CDMO Galenvs Sciences Inc. at a pre-money valuation of USD 3.50 million

Laurus Labs Acquires 60% Stake in Canada-Based Galenvs Sciences for USD 3.75 Million

Laurus Labs Ltd 路 Others (Uncategorized) 路 29 Oct 2026, 8:33 pm

Laurus Labs Acquires 60% Stake in Canada-Based Galenvs Sciences for USD 3.75 Million Laurus Labs' board approved acquiring a 60% stake in Canada-based CRO/CDMO Galenvs Sciences Inc. at a pre-money valuation of USD 3.50 million. The total cash investment of USD 3.75 million comprises a USD 2.75 million primary infusion (44% diluted stake) and a USD 1.00 million secondary purchase (16% diluted stake). Galenvs specializes in custom oligonucleotide synthesis and magnetic-nanoparticle technologies, clocking CY25 revenue of CAD 1.65 million. The deal bolsters Laurus Labs' oligonucleotide R&D pipeline and expands its North American footprint.

Original exchange filing (PDF)

More announcements from Laurus Labs Ltd

All Laurus Labs Ltd announcements